<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5427">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03036293</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-TN-001</org_study_id>
    <nct_id>NCT03036293</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders</brief_title>
  <official_title>International Multicenter, Double-blind, Randomized Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of Different Dosing Regimens of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        -  To further examine the efficacy and safety of Tenoten® in the treatment of anxiety in
           patients with somatoform, stress-related and other neurotic disorders.

        -  To compare the efficacy of two dosing regimens of Tenoten® (4 tablets daily vs.8
           tablets daily, both for 12 weeks) in the treatment of anxiety in patients with
           somatoform, stress-related and other neurotic disorders.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean HAM-A score at 12 weeks of treatment in patients from: 1. Group 1 (Tenoten®, 4 tablets a day); 2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean HAM-A score at 4 weeks of treatment in patients from: 1.1. Group 1 (Tenoten®, 4 tablets a day); 1.2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean HAM-A score at 8 weeks of treatment versus baseline in patients from: 2.1. Group 1 (Tenoten®, 4 tablets a day); 2.2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving at least a 50% improvement in the HAM-A score from baseline in: 3.1. Group 1 (Tenoten®, 4 tablets a day) 3.1.1. at 4 weeks; 3.1.2. at 8 weeks; 3.1.3. at 12 weeks; 3.2. Group 3 (Tenoten®, 8 tablets a day) 3.2.1. at</measure>
    <time_frame>4,8,12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with no anxiety (HAM-A score &lt;14) in: 4.1. Group 1 (Tenoten®, 4 tablets a day) 4.1.1. at 4 weeks; 4.1.2. at 8 weeks; 4.1.3. at 12 weeks;</measure>
    <time_frame>4,8,12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the total EQ-5D-3L score at 12 weeks of treatment in patients from: 5.1. Group 1 (Tenoten®, 4 tablets a day); 5.2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total CGI scores in patients from: 6.1. Group 1 (Tenoten®, 4 tablets a day); 6.2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Tenoten, 2 tablets twice a day (4 tablets a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 2 tablets twice a day (4 tablets a day)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenoten, 2 tablets 4 times daily (8 tablets a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 2 tablets 4 times daily (8 tablets a day)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenoten</intervention_name>
    <description>Safety and Efficiency</description>
    <arm_group_label>Tenoten, 2 tablets twice a day (4 tablets a day)</arm_group_label>
    <arm_group_label>Tenoten, 2 tablets 4 times daily (8 tablets a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safety and Efficiency</description>
    <arm_group_label>Placebo, 2 tablets twice a day (4 tablets a day)</arm_group_label>
    <arm_group_label>Placebo, 2 tablets 4 times daily (8 tablets a day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes aged 18-45 years inclusively.

          2. Patients diagnosed with somatoform, stress-related, and other neurotic disorders
             (F43, F45, and F48) , in accordance with the ICD-10 criteria.

          3. A moderate and severe anxiety (HADS score ≥ 11) documented at screening.

          4. Patients providing signed Informed Consent form for participation in the clinical
             trial.

          5. Patients of reproductive age (of both sexes) using contraceptives and contraceptive
             methods during the study and for 30 days after the end of participation in the trial.

        Exclusion Criteria:

          1. Moderate and severe depression symptoms recorded at screening (HADS score ≥ 11).

          2. Organic, including symptomatic, mental disorders (F00-09).

          3. Mental and behavioural disorders due to psychoactive substance use (F10-19).

          4. Schizophrenia, schizotypal and delusional disorders (F20-29).

          5. Mood [affective] disorders(F30-39).

          6. Phobic (F40) and other anxiety disorders (F41), obsessive-compulsive disorder (F42),
             dissociative [conversion] disorders (F44), depersonalization-derealization syndrome
             (F48.1).

          7. Behavioral syndromes associated with physiological disturbances and physical factors
             (F50-59).

          8. Disorders of adult personality and behavior (F60-69).

          9. Intellectual disabilities (F70-79).

         10. Inflammatory and traumatic brain injuries with permanent neurological deficit.

         11. Prior diagnosis of a class III or IV cardiovascular disease (according to the New
             York Heart Association, 1964)

         12. Malignant neoplasms/suspected malignant neoplasms.

         13. An allergy/intolerance to any of the components of medications used in the treatment.

         14. Malabsorption syndrome (including hereditary or acquired lactase or other
             disaccharidase deficiency) and galactosemia.

         15. Any conditions that, from investigator's point of view, may affect the patient's
             ability to participate in the trial.

         16. Hospitalizations or surgeries scheduled for any date during the participation in the
             study.

         17. Patients who, from investigator's point of view, will fail to comply with the
             observation requirements of the trial or with the dosing regimen of the study drugs.

         18. Use of drugs listed in &quot;Prohibited drugs&quot; within a month prior to enrollment.

         19. Drug addiction, alcohol use in the amount over 2 units of alcohol a day.

         20. Pregnant or breast-feeding women.

         21. Participation in other clinical trials within 3 month prior to the enrollment in this
             study.

         22. Patients are related to the research personnel of the investigative site who are
             directly involved in the trial, or patients who are the immediate family member of
             the researcher. The 'immediate family member' includes husband/wife, parents,
             children or brothers (or sisters), regardless of whether they are natural or adopted.

         23. Patients works for OOO &quot;NPF &quot;MATERIA MEDICA HOLDING&quot;, i.e. is the company's employee,
             temporary contract worker, or appointed official responsible for carrying out the
             research (or the immediate relative).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD</last_name>
    <phone>+74952761571</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>The State Autonomic Health Care institution &quot;Interregional clinical and diagnostical center&quot;</name>
      <address>
        <city>Kazan'</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Hasanova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Dina Hasanova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Family policlinic no. 4&quot;</name>
      <address>
        <city>Korolev</city>
        <zip>141060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Glushkov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Konstantin Glushkov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budget Health Care institution of Moscow the City &quot;Scientific and practical psychoneurological center n.a. Z.P. Solovyov&quot; of the Administration of Health Care of Moscow City</name>
      <address>
        <city>Moscow</city>
        <zip>115419</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Gecht, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Alla Gecht, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Care institution of Moscow the City &quot;City clinical hospital No. 12 of the Administration of Health Care of Moscow City&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115516</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Kamchatnov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Pavel Kamchatnov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Educational institution of High Professional Training I.M. Sechenov First Moscow State Medical University of Ministry of Health Care of the Russian Federation, Hospital of nervous diseases A.Y. Kozhevnikov</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladimir Parfenov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Parfenov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Educational institution of High Professional Training Smolensk State Medical University of Ministry of Health Care of the Russian Federation, Smolensk regional clinical hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Maslova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Natalya Maslova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Health Care Institution Yaroslavl region &quot;Clinical Hospital №8</name>
      <address>
        <city>Yaroslavl'</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalya Pizova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Natalya Pizova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>January 26, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Neurotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
